MX2023000658A - Composiciones utiles para el tratamiento de la enfermedad de charcot-marie-tooth. - Google Patents
Composiciones utiles para el tratamiento de la enfermedad de charcot-marie-tooth.Info
- Publication number
- MX2023000658A MX2023000658A MX2023000658A MX2023000658A MX2023000658A MX 2023000658 A MX2023000658 A MX 2023000658A MX 2023000658 A MX2023000658 A MX 2023000658A MX 2023000658 A MX2023000658 A MX 2023000658A MX 2023000658 A MX2023000658 A MX 2023000658A
- Authority
- MX
- Mexico
- Prior art keywords
- coding sequence
- human
- mirna
- compositions useful
- mitofusin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 title 1
- 108091026890 Coding region Proteins 0.000 abstract 5
- 101001018717 Homo sapiens Mitofusin-2 Proteins 0.000 abstract 4
- 102000057083 human MFN2 Human genes 0.000 abstract 4
- 108091070501 miRNA Proteins 0.000 abstract 4
- 239000002679 microRNA Substances 0.000 abstract 4
- 201000008990 Charcot-Marie-Tooth disease type 2A1 Diseases 0.000 abstract 2
- 208000035758 Charcot-Marie-Tooth disease type 2S Diseases 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- HISOCSRUFLPKDE-KLXQUTNESA-N cmt-2 Chemical compound C1=CC=C2[C@](O)(C)C3CC4C(N(C)C)C(O)=C(C#N)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O HISOCSRUFLPKDE-KLXQUTNESA-N 0.000 abstract 2
- 150000007523 nucleic acids Chemical group 0.000 abstract 2
- 230000001105 regulatory effect Effects 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063051336P | 2020-07-13 | 2020-07-13 | |
| US202163173045P | 2021-04-09 | 2021-04-09 | |
| PCT/US2021/041406 WO2022015715A1 (en) | 2020-07-13 | 2021-07-13 | Compositions useful for treatment of charcot-marie-tooth disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023000658A true MX2023000658A (es) | 2023-02-23 |
Family
ID=77317406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023000658A MX2023000658A (es) | 2020-07-13 | 2021-07-13 | Composiciones utiles para el tratamiento de la enfermedad de charcot-marie-tooth. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230270884A1 (enExample) |
| EP (1) | EP4179097A1 (enExample) |
| JP (1) | JP2023534037A (enExample) |
| KR (1) | KR20230038503A (enExample) |
| CN (1) | CN116438311A (enExample) |
| AU (1) | AU2021309645A1 (enExample) |
| BR (1) | BR112023000578A2 (enExample) |
| CA (1) | CA3185281A1 (enExample) |
| CO (1) | CO2023001500A2 (enExample) |
| IL (1) | IL299762A (enExample) |
| MX (1) | MX2023000658A (enExample) |
| TW (1) | TW202216244A (enExample) |
| WO (1) | WO2022015715A1 (enExample) |
| ZA (1) | ZA202300505B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4405469A4 (en) * | 2021-09-24 | 2025-09-10 | Univ Pennsylvania | COMPOSITIONS FOR THE TREATMENT OF CHARCOT-MARIE-TOOTH DISEASE |
| WO2024130067A2 (en) | 2022-12-17 | 2024-06-20 | The Trustees Of The University Of Pennsylvania | Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same |
| WO2024130070A2 (en) | 2022-12-17 | 2024-06-20 | The Trustees Of The University Of Pennsylvania | Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof |
| WO2024155966A1 (en) * | 2023-01-20 | 2024-07-25 | Loma Linda University Health | Methods and compositions for treatment of niemann-pick disease type c and charcot-marie-tooth disease |
| WO2024261139A1 (en) | 2023-06-21 | 2024-12-26 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | Variants of mfn2 and their use in the treatment/prevention of diseases associated with alterations in endoplasmatic reticulum function |
| WO2025007046A1 (en) | 2023-06-29 | 2025-01-02 | The Trustees Of The University Of Pennsylvania | Mutant aav with central nervous system targeting motifs and compositions containing same |
| WO2025106661A1 (en) | 2023-11-14 | 2025-05-22 | The Trustees Of The University Of Pennsylvania | Compositions with cardiac and skeletal musclespecific targeting motifs and uses thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6759237B1 (en) | 1998-11-05 | 2004-07-06 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
| ATE317916T1 (de) | 2001-11-13 | 2006-03-15 | Univ Pennsylvania | Verfahren zur identifizierung von adeno- assoziiertem virus (aav) sequenzen sowie kit zur ausführung der methode |
| EP1453547B1 (en) | 2001-12-17 | 2016-09-21 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (aav) serotype 8 sequences, vectors containing same, and uses therefor |
| ES2874298T3 (es) | 2003-09-30 | 2021-11-04 | Univ Pennsylvania | Clados de virus adenoasociados (AAV), secuencias, vectores que contienen el mismo, y usos de los mismos |
| ES2428218T3 (es) | 2005-04-07 | 2013-11-06 | The Trustees Of The University Of Pennsylvania | Cápsides de AAV rh48 modificadas, composiciones que las contienen y usos de las mismas |
| US7588772B2 (en) | 2006-03-30 | 2009-09-15 | Board Of Trustees Of The Leland Stamford Junior University | AAV capsid library and AAV capsid proteins |
| US8969353B2 (en) | 2008-11-07 | 2015-03-03 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| US20130023033A1 (en) | 2010-03-29 | 2013-01-24 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
| US20130037977A1 (en) | 2010-04-08 | 2013-02-14 | Paul A. Burke | Preparation of Lipid Nanoparticles |
| US8853377B2 (en) | 2010-11-30 | 2014-10-07 | Shire Human Genetic Therapies, Inc. | mRNA for use in treatment of human genetic diseases |
| JP6184945B2 (ja) | 2011-06-08 | 2017-08-23 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | ｍＲＮＡ送達のための脂質ナノ粒子組成物および方法 |
| FR2977562B1 (fr) | 2011-07-06 | 2016-12-23 | Gaztransport Et Technigaz | Cuve etanche et thermiquement isolante integree dans une structure porteuse |
| DK2858677T3 (da) | 2012-06-08 | 2020-08-31 | Ethris Gmbh | Pulmonær levering af messenger rna |
| EP4331620A3 (en) | 2012-12-07 | 2024-12-04 | Translate Bio, Inc. | Lipidic nanoparticles for mrna delivery |
| KR102095085B1 (ko) | 2013-11-18 | 2020-03-31 | 아크투루스 쎄라퓨틱스, 인크. | Rna 전달을 위한 이온화가능한 양이온성 지질 |
| EP3387117B1 (en) | 2015-12-11 | 2022-11-23 | The Trustees Of The University Of Pennsylvania | Scalable purification method for aav8 |
| EP3992283A1 (en) | 2015-12-11 | 2022-05-04 | The Trustees Of The University Of Pennsylvania | Scalable purification method for aavrh10 |
| US11098286B2 (en) | 2015-12-11 | 2021-08-24 | The Trustees Of The University Of Pennsylvania | Scalable purification method for AAV9 |
| WO2017100674A1 (en) | 2015-12-11 | 2017-06-15 | The Trustees Of The University Of Pennsylvania | Scalable purification method for aav1 |
| WO2018160582A1 (en) | 2017-02-28 | 2018-09-07 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (aav) clade f vector and uses therefor |
| WO2018168961A1 (ja) | 2017-03-16 | 2018-09-20 | 株式会社デンソー | 自己位置推定装置 |
| US12416016B2 (en) | 2018-02-27 | 2025-09-16 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) vectors, AAV vectors having reduced capsid deamidation and uses therefor |
| EP3758724A4 (en) | 2018-02-27 | 2022-07-06 | The Trustees of The University of Pennsylvania | NOVEL VECTORS OF ADENO-ASSOCIATED VIRUS (AAV), AAV VECTORS WITH REDUCED CAPSIID DEAMIDATION AND USES THEREOF |
| AU2019328270A1 (en) * | 2018-08-29 | 2021-03-25 | Research Institute At Nationwide Children's Hospital | Products and methods for inhibition of expression of mutant GARS protein |
| AU2019401314A1 (en) | 2018-12-21 | 2021-06-24 | The Trustees Of The University Of Pennsylvania | Compositions for DRG-specific reduction of transgene expression |
-
2021
- 2021-07-13 JP JP2023502675A patent/JP2023534037A/ja active Pending
- 2021-07-13 IL IL299762A patent/IL299762A/en unknown
- 2021-07-13 BR BR112023000578A patent/BR112023000578A2/pt unknown
- 2021-07-13 CN CN202180062652.6A patent/CN116438311A/zh active Pending
- 2021-07-13 TW TW110125641A patent/TW202216244A/zh unknown
- 2021-07-13 MX MX2023000658A patent/MX2023000658A/es unknown
- 2021-07-13 CA CA3185281A patent/CA3185281A1/en active Pending
- 2021-07-13 EP EP21754870.0A patent/EP4179097A1/en active Pending
- 2021-07-13 US US18/005,504 patent/US20230270884A1/en active Pending
- 2021-07-13 WO PCT/US2021/041406 patent/WO2022015715A1/en not_active Ceased
- 2021-07-13 AU AU2021309645A patent/AU2021309645A1/en active Pending
- 2021-07-13 KR KR1020237003861A patent/KR20230038503A/ko active Pending
-
2023
- 2023-01-11 ZA ZA2023/00505A patent/ZA202300505B/en unknown
- 2023-02-10 CO CONC2023/0001500A patent/CO2023001500A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023000578A2 (pt) | 2023-05-09 |
| TW202216244A (zh) | 2022-05-01 |
| CN116438311A (zh) | 2023-07-14 |
| JP2023534037A (ja) | 2023-08-07 |
| CO2023001500A2 (es) | 2023-05-19 |
| CA3185281A1 (en) | 2022-01-20 |
| ZA202300505B (en) | 2023-09-27 |
| EP4179097A1 (en) | 2023-05-17 |
| US20230270884A1 (en) | 2023-08-31 |
| KR20230038503A (ko) | 2023-03-20 |
| WO2022015715A1 (en) | 2022-01-20 |
| IL299762A (en) | 2023-03-01 |
| AU2021309645A1 (en) | 2023-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202300505B (en) | Compositions useful for treatment of charcot-marie-tooth disease | |
| BR112021011143A2 (pt) | Composições para redução específica de drg da expressão de transgene | |
| WO2022076803A8 (en) | Compositions and methods for treatment of fabry disease | |
| MY208862A (en) | Factor viii (fviii) gene therapy methods | |
| MY209860A (en) | Gene therapy vectors for treating heart disease | |
| MX2023007574A (es) | "vacuna de arn contra variantes de sars-cov-2. | |
| MX2023011035A (es) | Composición de terapia génica y tratamiento de la miocardiopatía arritmogénica del ventriculo derecho. | |
| CO2021016323A2 (es) | Composiciones útiles en el tratamiento de leucodistrofia metacromática | |
| MX2019004843A (es) | Terapia genica para esclerosis lateral amiotrofica y otros trastornos de la medula espinal. | |
| JPWO2019156137A5 (enExample) | ||
| JP2014506787A5 (enExample) | ||
| MX2022013411A (es) | Genes gla con codones optimizados y usos de los mismos. | |
| CR20230577A (es) | Composiciones de suministro de terapia y métodos para tratar perdida auditiva | |
| AR037038A1 (es) | Una composicion y metodo para alterar la masa corporal magra y las propiedades oseas en un sujeto | |
| MX2022007546A (es) | Interferon-alfa-2 modificado que tiene inmunogenicidad reducida. | |
| DE19580890D2 (de) | Lebendvakzine zur Behandlung von Tumorerkrankungen | |
| MX2023006445A (es) | Composiciones y usos de estas para el tratamiento del síndrome de angelman. | |
| AR122957A1 (es) | Composiciones útiles para el tratamiento de la enfermedad de charcot-marie-tooth | |
| MX2023011875A (es) | Tratamiento genico para miocardiopatía arritmogénica del ventriculo derecho. | |
| MX2024004398A (es) | Peptidos y fragmentos para tratar diabetes y enfermedades metabolicas asociadas. | |
| CO6160332A2 (es) | Agente para terapia y/o mejoramiento de coagulacion intravascular diseminada | |
| MX2023009030A (es) | Composiciones y métodos para el tratamiento de enfermedad de niemann pick tipo a. | |
| MX2023006153A (es) | Terapias genicas para enfermedad neurodegenerativa. | |
| RU2006119452A (ru) | Рекомбинантный белок, обладающий противораковым действием, кодирующий его ген и его применение | |
| EA202191744A1 (ru) | Композиции для drg-специфического снижения экспрессии трансгена |